Dr. Kang on Aprepitant for Preventing CINV in Children
Hyoung Jin Kang, MD, PhD, associate professor, Department of Pediatrics, Seoul National University, South Korea, discusses a phase III trial of aprepitant for chemotherapy-induced nausea and vomiting (CINV) in children.
Following Reconstruction, Patients With Early Breast Cancer May Safely Opt For a Shorter Course of Radiation Therapy
PVd Confers a Small OS Benefit to Patients With Relapsed/Refractory Multiple Myeloma
Neoadjuvant Durvalumab Combination Misses Mark in EGFR+ NSCLC
Durvalumab Garners Similar OS, Albeit Varied PFS, Outcomes in EGFR+ and EGFR-Wildtype NSCLC Subgroups
